PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 12 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Polysaccharides (ESP and DSP) inhibited tumor cell proliferation and migration in vitro and in xenograft models [PMID:41819334].
Inonotus sanghuang extract (ISE) improved survival in bleomycin-induced mice by decreasing lung infiltrating cells, collagen deposition, and mesenchymal markers [PMID:33202282].
Polyphenols-rich extract improved pathological lung injury scores and reduced lung wet-to-dry ratios in bleomycin-induced mice [PMID:31152815].
Network pharmacology and simulations suggest therapeutic potential via the PI3K-Akt pathway [PMID:41137228].
Hispolon and its analogs improved learning functions in scopolamine-induced mice [PMID:39692936].
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 41819334 (2026) — Characterization and antitumor activities of polysaccharides derived from Inonotus sanghuang against cancers of the liver and lungs. · International journal of biological macromolecules
- 2.PMID: 33202282 (2021) — Mushroom Inonotus sanghuang alleviates experimental pulmonary fibrosis: Implications for therapy of pulmonary fibrosis. · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
- 3.PMID: 31394179 (2019) — Immunoregenerative effects of the bionically cultured Sanghuang mushrooms (Inonotus sanghuagn) on the immunodeficient mice. · Journal of ethnopharmacology
- 4.PMID: 38752831 (2025) — Whitening and antioxidant activities of Inonotus sanghuang Extract and development of primary whitening gel products. · Natural product research
- 5.PMID: 30863401